BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37187316)

  • 21. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
    Hanada KI; Zhao C; Gil-Hoyos R; Gartner JJ; Chow-Parmer C; Lowery FJ; Krishna S; Prickett TD; Kivitz S; Parkhurst MR; Wong N; Rae Z; Kelly MC; Goff SL; Robbins PF; Rosenberg SA; Yang JC
    Cancer Cell; 2022 May; 40(5):479-493.e6. PubMed ID: 35452604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
    Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
    Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
    Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
    Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
    Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
    Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.
    Wang Z; Cao YJ
    Front Immunol; 2020; 11():176. PubMed ID: 32194541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
    Yin Q; Tang J; Zhu X
    Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
    Ishihara M; Kitano S; Kageyama S; Miyahara Y; Yamamoto N; Kato H; Mishima H; Hattori H; Funakoshi T; Kojima T; Sasada T; Sato E; Okamoto S; Tomura D; Nukaya I; Chono H; Mineno J; Kairi MF; Diem Hoang Nguyen P; Simoni Y; Nardin A; Newell E; Fehlings M; Ikeda H; Watanabe T; Shiku H
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35768164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma.
    Schaettler MO; Desai R; Wang AZ; Livingstone AJ; Kobayashi DK; Coxon AT; Bowman-Kirigin JA; Liu CJ; Li M; Bender DE; White MJ; Kranz DM; Johanns TM; Dunn GP
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TCR validation toward gene therapy for cancer.
    Green EW; Bunse L; Bozza M; Sanghvi K; Platten M
    Methods Enzymol; 2019; 629():419-441. PubMed ID: 31727252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
    Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Strategies in TCR-Engineered T Cells.
    Wei F; Cheng XX; Xue JZ; Xue SA
    Front Immunol; 2022; 13():850358. PubMed ID: 35432319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.
    Poran A; Scherer J; Bushway ME; Besada R; Balogh KN; Wanamaker A; Williams RG; Prabhakara J; Ott PA; Hu-Lieskovan S; Khondker ZS; Gaynor RB; Rooney MS; Srinivasan L
    Cell Rep Med; 2020 Nov; 1(8):100141. PubMed ID: 33294862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
    Ren L; Leisegang M; Deng B; Matsuda T; Kiyotani K; Kato T; Harada M; Park JH; Saloura V; Seiwert T; Vokes E; Agrawal N; Nakamura Y
    Oncoimmunology; 2019; 8(4):e1568813. PubMed ID: 30906664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
    Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
    Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of Antigen-Specific T-Cell Receptor Clusters in Human Cancers.
    Zhang H; Liu L; Zhang J; Chen J; Ye J; Shukla S; Qiao J; Zhan X; Chen H; Wu CJ; Fu YX; Li B
    Clin Cancer Res; 2020 Mar; 26(6):1359-1371. PubMed ID: 31831563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects.
    Shafer P; Kelly LM; Hoyos V
    Front Immunol; 2022; 13():835762. PubMed ID: 35309357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
    Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
    Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
    Rath JA; Arber C
    Cells; 2020 Jun; 9(6):. PubMed ID: 32570906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.